Paper Details

  1. Home
  2. Paper Details

A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.

Author: AgostiniC, AnglaretB, BachelotT, BironP, BlayJ-Y, DebourdeauP, DesseigneF, DussartS, GhesquieresH, GoillotC, GuastallaJ-P, LancryL, Le CesneA, MayeurD, Ray-CoquardI

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Epoetin (EPO) administration can reduce the need for red blood cell transfusions. This study aimed to identify patients at high risk for anemia requiring transfusion and evaluate the effectiveness of EPOalpha administration based on a risk model using clinical parameters such as hemoglobin level, lymphocyte count, and performance status.
Paper Details　
Original Abstract of the Article :
Epoetin (EPO) administration reduces the need for transfusion. Identifying patients at high risk of anemia requiring red blood cell (RBC) transfusion is needed. This multicentric phase III trial tested epoetin alpha (EPOalpha) administration according to our risk model on the basis of three clinical...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/annonc/mdn750

データ提供：米国国立医学図書館（NLM）

Predicting Severe Anemia in Cancer Patients: A Risk Model for Epoetin Alpha Use

Cancer treatment can often lead to anemia, a condition where the blood lacks enough healthy red blood cells. This study examines the effectiveness of epoetin alpha, a medication that stimulates red blood cell production, in preventing severe anemia in cancer patients. Researchers are seeking to develop a risk model to identify patients who would most benefit from epoetin alpha treatment, like a skilled desert navigator carefully assessing the terrain to determine the best route for their journey.

Risk Model for Epoetin Alpha Use Shows Promise

The study found that a risk model based on hemoglobin levels, lymphocyte count, and performance status effectively identified patients who were at high risk for severe anemia requiring red blood cell transfusion. This model could help guide clinicians in making informed decisions about epoetin alpha treatment, potentially improving patient outcomes. This is like a desert explorer using a compass to navigate the right path, ensuring a safe and successful journey.

Navigating Cancer Treatment: A Multidisciplinary Approach

Cancer treatment is a complex process that often involves multiple disciplines, including oncology, hematology, and supportive care. This study underscores the importance of a multidisciplinary approach to managing side effects like anemia. Working closely with healthcare professionals can help ensure optimal care and support for cancer patients.

Dr.Camel's Conclusion

This study, like a shimmering oasis in the desert of cancer treatment, offers valuable insights into the potential for epoetin alpha to improve patient outcomes. By carefully assessing risk factors, healthcare professionals can provide targeted therapy and help cancer patients navigate this challenging journey.

Date :
  1. Date Completed 2009-07-02
  2. Date Revised 2020-02-03
Further Info :

Pubmed ID

19174452

DOI: Digital Object Identifier

10.1093/annonc/mdn750

Related Literature

Article Analysis
・Side Effects of epoetin alfa
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.